Clinical trial NCT00591812: Evaluation of the Compress Distal Femoral Replacement System
Official title: Evaluation of the Compress Distal Femoral Replacement System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Lower Thighbone and Knee Joint Replacement
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: Zimmer Biomet
First posted: 2008-01-11
Enrollment: 26
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Patients in this study require a replacement of a lower thighbone and knee joint. A new device, called the ComPreSs, will be used in this study to replace the lower thighbone. This new device has not yet been approved by the Food and Drug Administration (FDA). There is not enough data to assure that it is as good as other devices currently available. Taking part in this study will help provide data to the FDA. Other devices used to replace large pieces of bone and joints in the leg can result in damage to the bone over time. The bone damage can cause the device to come loose from the bone. This is a bad problem, and causes pain, and often more surgery is needed. This new device connects to the bone in a different way to prevent some of the problems seen with other devices. The new device protects the bone, and may help the replacement last longer. So far, the device has been used in over 50 patients on a selective basis.


Eligibility criteria: Inclusion Criteria:

* Patients with bone tumors of the distal femur requiring primary bone resection of up to 30 cm with the resection at or below the lesser trochanter.
* Patients with prior orthopaedic oncologic conditions requiring revisions of distal femoral replacement devices with a total replacement height of 30 cm or less and the resection level is at or below the lesser trochanter.
* Patients who have a cortical bone thickness of 2.5 mm or larger in the region where the ComPreSs device would be implanted.
* Patients diagnosed with a bone tumor classified as Stage 1A, IB, IIA, IIB, or III by Enneking's classification system. (See section 12.0, #7)

Exclusion Criteria:

* Patients with active infection.
* Patients who are unable to return for follow-up examinations.
* Patients who have cortical bone thickness less than 2.5 mm in the region where the ComPreSs device would be implanted.
* Patients who are unwilling or incapable of following postoperative care instructions.
* Patients requiring bilateral knee implants.
* Patients with evidence of vascular insufficiency (arterial and/or venous).
* Patients having Parkinson's disease, severe muscular atrophy, neuromuscular disease in the affected limb.
* Patients with prior irradiated bone.
* Patients with metastatic cancer including carcinoma, melanoma, myeloma, lymphoma, leukemia.
* Patients with pathologic soft tissue or skeletal conditions that would prevent secure fixation of the device in the bone.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: John Healey, MD
role: PRINCIPAL_INVESTIGATOR
References: